Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Velcheti, Vamsidhar; Kim, Edward S.; Mekhail, Tarek; Dakhil, Christopher; Stella, Philip J.; Shen, Xiaowei; Hu, Sylvia; Paul, Sarah M.; Shames, David S.; Yun, Cindy; Phan, See-Chun; Socinski, Mark A.

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15